Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Anoro Ellipta | Umeclidinium/vilanterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
| Invokana | Canagliflozin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
| Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ultibro Breezhaler | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
| Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
| Opsumit | Macitentan | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete |
Last Updated : May 18, 2024